ADVENZYMES Advanced Enzyme Technologies Q1 FY26 results (Apr–Jun 2025) and concall
Advanced Enzyme Technologies reported a strong Q1 FY26 with record revenue and significant PAT growth, primarily driven by Human and Animal Healthcare segments. Despite a temporary dip in Bioprocessing and pressure on gross margins due to product mix and US tariffs, the company is optimistic about long-term double-digit growth, supported by ongoing R&D and strategic initiatives including a new subsidiary for nutrition products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 77 | 101 | 87 | 125 |
| EBITDA | 14 | 22 | 14 | 31 |
| Net profit | 9 | 15 | 11 | 74 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
